8-KShareholder MattersOther EventsExhibits & Filings

BeOne Medicines Ltd. 8-K Report, Shareholder Vote Results (Jun 5, 2019)

Filed June 5, 2019For Securities:ONCBEIGF

Summary

BeiGene, Ltd. (the "Company") filed an 8-K on June 5, 2019, detailing the results of its 2019 Annual General Meeting of Shareholders. The meeting saw high shareholder participation, with over 89% of outstanding ordinary shares represented. Key outcomes include the re-election of four directors (Ranjeev Krishana, Xiaodong Wang, Qingqing Yi, and Jing-Shyh (Sam) Su), the ratification of Ernst & Young as the independent registered public accounting firm for fiscal year 2019, and the approval of a general mandate for the Board to issue shares up to 20% of the total issued shares. Additionally, shareholders approved a 'Connected Person Placing Authorization' to allow specific existing shareholders to maintain their percentage ownership after future offerings, and a non-binding advisory vote on executive compensation was also approved. Beyond the shareholder meeting, the Company also announced an amendment to its Independent Director Compensation Policy, which will now grant equity awards solely in the form of share options, valued at $300,000 for initial appointment and annually, to comply with Hong Kong Stock Exchange listing rules. The total compensation for independent directors, including cash and equity, will be capped at $1,000,000 per calendar year. Furthermore, an amendment to the 2018 Employee Share Purchase Plan was approved, removing the six-month waiting period for employee participation.

Key Highlights

  • 1High shareholder turnout at the 2019 Annual General Meeting, with approximately 89.1% of ordinary shares represented.
  • 2All four nominated directors (Ranjeev Krishana, Xiaodong Wang, Qingqing Yi, Jing-Shyh (Sam) Su) were successfully re-elected.
  • 3Ernst & Young was ratified as the Company's independent registered public accounting firm for fiscal year 2019.
  • 4Shareholders approved a general mandate allowing the Board to issue new shares equivalent to up to 20% of the total issued shares.
  • 5A 'Connected Person Placing Authorization' was approved, permitting specific existing shareholders to maintain their ownership percentage in future offerings.
  • 6The Independent Director Compensation Policy was amended to exclusively use share options for equity awards, with annual grants valued at $300,000.
  • 7The Employee Share Purchase Plan was amended to eliminate the six-month waiting period for employee eligibility.

Frequently Asked Questions

The primary outcomes included the re-election of four directors, the ratification of Ernst & Young as the auditor, approval of a general mandate for share issuance, and the approval of a 'Connected Person Placing Authorization'. Additionally, shareholders provided an advisory vote on executive compensation.

The policy was amended to grant equity awards solely in the form of share options, replacing the previous mix of share options and restricted share units. This change was made to comply with Hong Kong Stock Exchange listing rules. Independent directors will receive $300,000 worth of share options upon initial appointment and annually, with certain vesting conditions.

This authorization allows the Company and its underwriters to allocate shares in future offerings to specific existing shareholders (Baker Bros. Advisors LP and Hillhouse Capital Management, Ltd.) to maintain their ownership percentage for a period of five years. This could be important for these key investors to maintain their influence or stake in the company without dilution from their perspective.

Yes, Amendment No. 1 to the Second Amended and Restated 2018 Employee Share Purchase Plan was approved. This amendment removes the previous six-month waiting period, making employees eligible to participate in the plan immediately upon commencement of an offering enrollment period.